法瑞西单抗与阿柏西普在新生血管性年龄相关性黄斑变性TENAYA/LUCERNE试验头对头给药期的解剖学结局比较
该研究为TENAYA/LUCERNE两项相同的随机、双盲、活性对照3期非劣效试验的汇总分析,纳入1329例未治疗的新生血管性年龄相关性黄斑变性患者,比较法瑞西单抗与阿柏西普在初始12周头对头给药期的早期解剖学结局。结果显示法瑞西单抗在降低中央亚区厚度和实现视网膜下液及视网膜内液与视网膜下液同时消失方面优于阿柏西普,且视网膜液首次消失时间更早。
要点
- 法瑞西单抗组第4、8、12周中央亚区厚度较基线的降幅大于阿柏西普组(名义P<0.0001)。
- 第12周无视网膜下液比例法瑞西单抗组87.9% vs 阿柏西普组79.0%。
- 第12周无视网膜内液和视网膜下液比例法瑞西单抗组77.2% vs 阿柏西普组66.5%。
核心结论
- 在头对头给药期,法瑞西单抗较阿柏西普带来更大的解剖学结局改善,且视网膜液首次消失时间更快。
研究设计与样本
- TENAYA/LUCERNE(NCT03823287/NCT03823300)为两项相同的随机、双盲、活性对照3期非劣效试验的汇总分析。
- 纳入年龄≥50岁、未治疗的新生血管性年龄相关性黄斑变性患者,共1329例(法瑞西单抗665例,阿柏西普664例)。
- 患者按1:1随机接受玻璃体腔内法瑞西单抗6.0 mg(初始4剂每4周一次后最多每16周一次)或阿柏西普2.0 mg(初始3剂每4周一次后每8周一次)。
主要发现
- 第4、8、12周时,法瑞西单抗组经调整的中央亚区厚度较基线平均降幅大于阿柏西普组(名义P<0.0001),视力结局相当。
- 第12周无视网膜下液比例:法瑞西单抗组87.9%(95%CI 85.4%-90.4%) vs 阿柏西普组79.0%(95%CI 76.0%-82.1%)。
- 第12周无视网膜内液和视网膜下液比例:法瑞西单抗组77.2%(95%CI 74.0%-80.4%) vs 阿柏西普组66.5%(95%CI 62.9%-70.0%)。
- 第12周无视网膜内液比例:法瑞西单抗组88.4%(95%CI 86.0%-90.8%) vs 阿柏西普组85.0%(95%CI 82.3%-87.6%)。
- 基线有视网膜内液或视网膜下液的患者中(法瑞西单抗581例,阿柏西普591例),视网膜内液和视网膜下液首次消失时间的第75百分位法瑞西单抗组为第8周、阿柏西普组为第12周;第12周累积发生率分别为85.5%(95%CI 82.3%-88.1%)和75.0%(95%CI 71.3%-78.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare early anatomic outcomes after treatment with faricimab versus aflibercept in a pooled analysis of the head-to-head dosing phase of the TENAYA/LUCERNE trials in neovascular age-related macular degeneration (nAMD). DESIGN: TENAYA/LUCERNE (NCT03823287/NCT03823300) were identical, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials. PARTICIPANTS: Patients aged ≥ 50 years with treatment-naïve nAMD. METHODS: Patients were randomized (1:1) to intravitreal faricimab 6.0 mg up to every 16 weeks (Q16W) after 4 initial doses every 4 weeks (Q4W) or aflibercept 2.0 mg every 8 weeks (Q8W) after 3 initial doses given Q4W. MAIN OUTCOME MEASURES: Post hoc analyses comparing faricimab with aflibercept in terms of change in central subfield thickness (CST) from baseline and proportion of patients with an absence of subretinal fluid (SRF) and intraretinal fluid (IRF) during initial 12-week head-to-head dosing phase, when both arms received 3 injections, and time to first absence of IRF and SRF. RESULTS: A total of 1329 patients were enrolled across TENAYA/LUCERNE (n = 665 faricimab; n = 664 aflibercept). There were greater (nominal P < 0.0001) reductions in adjusted mean CST from baseline with faricimab versus aflibercept at weeks 4, 8, and 12, with comparable vision outcomes. At week 12, more patients (95% confidence interval) achieved an absence of SRF (87.9% [85.4%-90.4%] vs. 79.0% [76.0%-82.1%]) and both IRF and SRF (77.2% [74.0%-80.4%] vs. 66.5% [62.9%-70.0%]) but not IRF (88.4% [86.0%-90.8%] vs. 85.0% [82.3%-87.6%]), with faricimab versus aflibercept, respectively. In patients with IRF or SRF at baseline (n = 581 faricimab; n = 591 aflibercept), the 75th percentile of time to first absence of IRF and SRF was reached at week 8 with faricimab and week 12 with aflibercept. At week 12, cumulative incidence of first-time absence of IRF and SRF was 85.5% (82.3%-88.1%) with faricimab and 75.0% (71.3%-78.3%) with aflibercept. CONCLUSIONS: Faricimab resulted in greater improvement in anatomic outcomes than aflibercept during the head-to-head dosing phase and a faster time to first absence of retinal fluid. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Cheung CMG, Lim JI, Priglinger S, et al. Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. Ophthalmology. 2024. PMID: 39617060. doi:10.1016/j.ophtha.2024.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。